Police Expose Shocking $1.3M Luxury Prostitution Ring, F1 Driver Involved
There is a lot that often goes on at high-profile parties that is brushed under the carpet, or…
Trans Canada Gold Completes the Acquisition of the Harrison Lake District Scale Gold Property and First Tranche of the Non-Brokered Private Placement
VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / Trans Canada Gold Corp. (TSXV:TTG)(OTCQB:TTGXF) (“Trans Canada” or…
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically…
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported…
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia;…
Scandium Canada Announces $10 Million Bought Deal Life Offering of Units
Montreal, Quebec–(Newsfile Corp. – March 3, 2026) – Scandium Canada Ltd. (TSXV: SCD) (the “Company”) is pleased to…
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
Amphastar Announces FDA Approval for Teriparatide Injection
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the…
Canada Nickel Announces Bought Deal Private Placement is Oversubscribed and Fully Allocated
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 24,…
Star Copper Advancing Canada’s Next Cu-Au Porphyry Discovery with Completion of Three Step-Out Holes at Star Main
Phase 2 Drill Program Extends Mineralized Corridor to the North and West, with 11 drill hole assays still…
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…